Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. the CORES Study

Nephrology Dialysis Transplantation

Volumn 26, Issue 6, 2011, Pages 1938-1947

  Naves Daz, Manuel ^a,d   Passlick Deetjen, Jutta ^b   Guinsburg, Adrian ^b   Marelli, Cristina ^b   Fernndez Martn, Jose Luis ^a,d   Rodrguez Puyol, Diego ^c,d   Cannata Anda, Jorge B ^a,d  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b FRESENIUS MEDICAL CARE   (Germany)

^c HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^d Instituto Reina Sofa de Investigacin   (Spain)

Author keywords

CORES Study; haemodialysis; mineral metabolism; mortality risk

Indexed keywords

ALBUMIN; ALFACALCIDOL; CALCITRIOL; CALCIUM; CREATININE; FERRITIN; HEMOGLOBIN; PARATHYROID HORMONE; PHOSPHATE;

ADULT; AGE DISTRIBUTION; ALBUMIN BLOOD LEVEL; ARTICLE; BLOOD PRESSURE; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; FERRITIN BLOOD LEVEL; GEOGRAPHIC DISTRIBUTION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; REFERENCE VALUE; RISK ASSESSMENT; SEX DIFFERENCE; SOUTH AND CENTRAL AMERICA; TREATMENT DURATION; VASCULAR ACCESS;

CALCIUM; CARDIOVASCULAR DISEASES; COHORT STUDIES; CREATININE; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; LATIN AMERICA; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHORUS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 79958133805     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq304     Document Type: Article

References (42)

1. Moe S, Drueke T, Cunningham J et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69: 1945-1953. (Pubitemid 43924257)
2. Cannata-Andia JB. Changing the current terminology in medicine- always a challenge. Nephrol Dial Transplant 2007; 22: 1811-1812. (Pubitemid 47244744)
3. Stevens LA, Djurdjev O, Cardew S et al. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 2004; 15: 770-779. (Pubitemid 38294808)
4. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218. (Pubitemid 39031360)
5. Block GA, Hulbert-Shearon TE, Levin NW et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-617.
6. Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 2005; 16: 1788-1793. (Pubitemid 41716485)
7. Kestenbaum B, Sampson JN, Rudser KD et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005; 16: 520-528. (Pubitemid 41725150)
8. Kalantar-Zadeh K, Kuwae N, Regidor DL et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771-780. (Pubitemid 44215354)
9. Tentori F, Blayney MJ, Albert JM et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008; 52: 519-530.
10. Young EW, Albert JM, Satayathum S et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005; 67: 1179-1187. (Pubitemid 41623345)
11. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: S1-S201.
12. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int 2009; 76: S1-S130.
13. Clase CM, Norman GL, Beecroft ML et al. Albumin-corrected calcium and ionized calcium in stable haemodialysis patients. Nephrol Dial Transplant 2000; 15: 1841-1846.
14. Noordzij M, Korevaar JC, Bos WJ et al. Mineral metabolism and cardiovascular morbidity and mortality risk: peritoneal dialysis patients compared with haemodialysis patients. Nephrol Dial Transplant 2006; 21: 2513-2520. (Pubitemid 44644525)
15. Tentori F, Hunt WC, Stidley CA et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006; 70: 1858-1865. (Pubitemid 44684819)
16. Dhingra R, Sullivan LM, Fox CS et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007; 167: 879-885. (Pubitemid 46762749)
17. Kimata N, Albert JM, Akiba T et al. Association of mineral metabolism factors with all-cause and cardiovascular mortality in hemodialysis patients: the Japan Dialysis Outcomes and Practice Patterns Study. Hemodial Int 2007; 11: 340-348. (Pubitemid 46958589)
18. Phelan PJ, O'Kelly P, Walshe JJ et al. The importance of serum albumin and phosphorous as predictors of mortality in ESRD patients. Ren Fail 2008; 30: 423-429. (Pubitemid 351868691)
19. Foundation NK. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: S1-S201.
20. Foley RN, Parfrey PS, Harnett JD et al. Hypocalcemia, morbidity, and mortality in end-stage renal disease. Am J Nephrol 1996; 16: 386-393. (Pubitemid 26316938)
21. Melamed ML, Eustace JA, Plantinga L et al. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int 2006; 70: 351-357. (Pubitemid 44086585)
22. de Francisco AL. Secondary hyperparathyroidism: review of the disease and its treatment. Clin Ther 2004; 26: 1976-1993. (Pubitemid 40353608)
23. Henrich WL, Hunt JM, Nixon JV. Increased ionized calcium and left ventricular contractility during hemodialysis. N Engl J Med 1984; 310: 19-23. (Pubitemid 14212476)
24. Riggs JE. Neurologic manifestations of electrolyte disturbances. Neurol Clin 2002; 20: 227-239. (Pubitemid 34111660)
25. Covic A, Kothawala P, Bernal M et al. Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant 2009; 24: 1506-1523.
26. Iyemere VP, Proudfoot D, Weissberg PL et al. Vascular smooth muscle cell phenotypic plasticity and the regulation of vascular calcification. J Intern Med 2006; 260: 192-210. (Pubitemid 44253633)
27. Giachelli CM. Vascular calcification mechanisms. J Am Soc Nephrol 2004; 15: 2959-2964. (Pubitemid 39578826)
28. Isakova T, Gutierrez OM, Chang Y et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol 2009; 20: 388-396.
29. Ayus JC, Achinger SG, Mizani MR et al. Phosphorus balance and mineral metabolism with 3 h daily hemodialysis. Kidney Int 2007; 71: 336-342. (Pubitemid 46227093)
30. Roman-Garcia P, Carrillo-Lopez N, Fernandez-Martin JL et al. High phosphorus diet induces vascular calcification, a related decrease in bone mass and changes in the aortic gene expression. Bone 2010; 46: 121-128.
31. Koch M, Lund R, Oldemeyer B et al. Refeeding hypophosphatemia in a chronically hyperphosphatemic hemodialysis patient. Nephron 2000; 86: 552. (Pubitemid 32008873)
32. Marinella MA. The refeeding syndrome and hypophosphatemia. Nutr Rev 2003; 61: 320-323. (Pubitemid 37259925)
33. Guh JY, Chen HC, Chuang HY et al. Risk factors and risk for mortality of mild hypoparathyroidism in hemodialysis patients. Am J Kidney Dis 2002; 39: 1245-1254.
34. Avram MM, Mittman N, Myint MM et al. Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation. Am J Kidney Dis 2001; 38: 1351-1357. (Pubitemid 34193126)
35. Naves-Diaz M, Alvarez-Hernandez D, Passlick-Deetjen J et al. Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int 2008; 74: 1070-1078.
36. Teng M, Wolf M, Ofsthun MN et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115-1125. (Pubitemid 41710323)
37. TsuchihashiK, TakizawaH, Torii Tet al.Hypoparathyroidismpotentiates cardiovascular complications through disturbed calcium metabolism: possible risk of vitamin D(3) analog administration in dialysis patients with end-stage renal disease. Nephron 2000; 84: 13-20. (Pubitemid 30066137)
38. Souberbielle JC, Boutten A, Carlier MC et al. Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int 2006; 70: 345-350. (Pubitemid 44086584)
39. Wolf M, Shah A, Gutierrez O et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007; 72: 1004-1013. (Pubitemid 47530570)
40. Levin A, Li YC. Vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease? Kidney Int 2005; 68: 1973-1981. (Pubitemid 43117772)
41. Oliveri B, Plantalech L, Bagur A et al. High prevalence of vitamin D insufficiency in healthy elderly people living at home in Argentina. Eur J Clin Nutr 2004; 58: 337-342. (Pubitemid 38256589)
42. Saraiva GL, Cendoroglo MS, Ramos LR et al. Influence of ultraviolet radiation on the production of 25 hydroxyvitamin D in the elderly population in the city of Sao Paulo 23 degrees 34'S, Brazil. Osteoporos Int 2005; 16: 1649-1654 (Pubitemid 41790871)